BioMS Medical retains ICON for pivotal MS trial: "BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has signed a letter of intent establishing ICON as the global clinical research organization (CRO) for the Company's ongoing pivotal phase II/III clinical trial for MBP8298 for the treatment of MS...... 'ICON has identified additional clinical trial sites in Europe that will ensure the timely completion of enrollment of our trial in mid-2006. We now anticipate up to an estimated 50 sites will be participating across Canada and Europe.'"